利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

387 条记录 (耗时 0.03 秒)

    METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASE
    6.
    发明申请
    METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASE 审中-公开
    用于诊断和治疗炎症性皮肤病的方法

    公开(公告)号：WO2017019673A2

    公开(公告)日：2017-02-02

    申请号：PCT/US2016/044022

    申请日：2016-07-26

    申请人： GENENTECH, INC. ,  F. HOFFMANN-LA ROCHE AG

    发明人： MONTAGUT, Teresa Ramirez ,  CHAI, Akiko ,  FUH, Franklin

    IPC分类号： G01N33/50

    CPC分类号： G01N33/505 ,  G01N2800/065 ,  G01N2800/52

    摘要： Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.

    摘要翻译： 提供了预测对整合素β7拮抗剂（包括抗β7整联蛋白亚单位抗体）的反应性的生物标志物和使用这些生物标志物的方法。 此外，提供了治疗胃肠道炎症性疾病如包括溃疡性结肠炎和克罗恩病的炎症性肠病的方法。 还提供了使用这种预测性生物标志物治疗包括溃疡性结肠炎和克罗恩病的炎症性肠病的方法。

    ASSAY
    7.
    发明申请
    ASSAY 审中-公开

    公开(公告)号：WO2016120632A1

    公开(公告)日：2016-08-04

    申请号：PCT/GB2016/050199

    申请日：2016-01-29

    申请人： THE UNIVERSITY OF BIRMINGHAM

    发明人： AFFORD, Simon ,  WILHELM, Annika

    IPC分类号： G01N33/574 ,  G01N33/68

    CPC分类号： G01N33/57438 ,  G01N33/6893 ,  G01N2800/065 ,  G01N2800/08 ,  G01N2800/085

    摘要： The invention provides a method of diagnosis or prognosis of a chronic liver disease or inflammatory bowel disease (IBD) in a subject comprising providing a sample from the subject and measuring the amount of TWEAK (tumour necrosis factor-like weak inducer of apoptosis) in the sample, wherein if the amount of TWEAK is below a predetermined level, then there is an increased risk that the subject has a chronic liver disease or has a poor prognosis of the chronic liver disease, or if the amount is above a predetermined level then there is an increased risk that the subject has IBD. The invention also provides a method of determining the effect of treatment on a chronic liver disease comprising providing measuring the amount of TWEAK in a first sample from a subject, provided before the treatment and comparing it to an amount of TWEAK in a second sample from a subject provided after treatment, wherein an increase in TWEAK between the first and second samples indicates that the chronic liver disease is being treated. Assay kits for use in the invention are also provided.

    摘要翻译： 本发明提供了一种在受试者中诊断或预后的慢性肝病或炎性肠病（IBD）的方法，包括从受试者提供样品并测量TWEAK（肿瘤坏死因子样弱凋亡诱导剂）的量 样本，其中如果TWEAK的量低于预定水平，则受试者具有慢性肝病或慢性肝病的预后不良的风险增加，或者如果该量高于预定水平，那么那里 受试者患IBD的风险增加。 本发明还提供了一种确定治疗对慢性肝病的影响的方法，包括提供在治疗前提供的测量来自受试者的第一样品中TWEAK的量，并将其与第二样品中TWEAK的量 治疗后提供受试者，其中第一和第二样品之间TWEAK的增加表明正在治疗慢性肝病。 还提供了用于本发明的测定试剂盒。

    METHODS FOR PREDICTION OF ANTI-TNF ALPHA DRUG LEVELS AND AUTOANTIBODY FORMATION
    10.
    发明申请
    METHODS FOR PREDICTION OF ANTI-TNF ALPHA DRUG LEVELS AND AUTOANTIBODY FORMATION 审中-公开
    用于预测抗TNF ALPHA药物水平和自身免疫形成的方法

    公开(公告)号：WO2016063204A1

    公开(公告)日：2016-04-28

    申请号：PCT/IB2015/058048

    申请日：2015-10-19

    申请人： NESTEC S.A.

    发明人： SINGH, Sharat ,  KONDRAGUNTA, Venkateswarlu

    IPC分类号： G01N33/50 ,  G01N33/564

    CPC分类号： G01N33/564 ,  G01N33/5091 ,  G01N33/6869 ,  G01N33/94 ,  G01N2333/5421 ,  G01N2333/5434 ,  G01N2800/065 ,  G01N2800/52

    摘要： In some aspects, the present invention provides methods for predicting whether a subject will develop autoantibodies to an anti-TNFα drug during the course of anti- TNFα drug therapy. In other aspects, the present invention provides methods for predicting the level of an anti-TNFα drug in a subject during the course of anti-TNFα drug therapy. Systems for predicting anti-TNFα drug levels and the likelihood of autoantibody formation during the course of anti-TNFα drug therapy are also provided herein. The present invention further provides methods for predicting a clinical outcome (e.g., endoscopic response) of a subject on anti-TNFα drug therapy.

    摘要翻译： 在一些方面，本发明提供了在抗TNFα药物治疗过程中预测受试者是否会向抗TNFα药物发展自身抗体的方法。 在其他方面，本发明提供了在抗TNFα药物治疗过程中预测受试者中抗TNFα药物水平的方法。 本文还提供了在抗TNFα药物治疗过程中预测抗TNFα药物水平和自身抗体形成的可能性的系统。 本发明还提供了用于预测受试者对抗TNFα药物治疗的临床结果（例如内镜反应）的方法。